Arlington Partners LLC Vertex Pharmaceuticals Inc Transaction History

Arlington Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 26, 2023	SELL	$314.42 - $351.91 $20,751 - $23,226	-66 Reduced 66.0%	34 $11,000
Q1 2023 Apr 26, 2023	BUY	$283.23 - $323.1 $28,323 - $32,310	100 New	100 $31,000
Q1 2022 Apr 14, 2022	SELL	$221.42 - $260.97 $10,849 - $12,787	-49 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$177.01 - $223.45 $8,673 - $10,949	49 New	49 $11,000
Q2 2020 Jul 13, 2020	SELL	$225.48 - $295.8 $10,372 - $13,606	-46 Closed	0 $0
Q4 2019 Jan 16, 2020	BUY	$166.71 - $223.91 $7,668 - $10,299	46 New	46 $10,000
Q1 2019 Apr 05, 2019	SELL	$163.73 - $194.7 $7,531 - $8,956	-46 Closed	0 $0
Q4 2018 Jan 10, 2019	BUY	$151.91 - $192.21 $6,987 - $8,841	46 New	46 $8,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Arlington Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Arlington Partners LLC with notifications on news.